[Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
The results of orchiectomy + flutamide (n = 28) versus orchiectomy + estramustine (n = 27) in the initial therapy of advanced prostatic cancer were compared in a prospective randomized study. The minimum observation period was one year. In the group orchiectomy + flutamide the incidence of side effects was 25%, the response rate (complete + partial remission) was 28% and the progression rate was 18%. 5 patients (18%) died within the first year. In the group orchiectomy + estramustine the incidence of side effects was 22%, the response rate (complete + partial remission) was 29% and the progression rate was 33%. 2 patients (7%) died within 1 year of treatment. There is no significant difference either in the response rate or the progression rate between the two groups.
Flamm
J
J
Urologische Abteilung, Wilhelminenspital der Stadt Wien.
Fischer
M
M
D000368:Aged; D000369:Aged, 80 and over; D000813:Anilides / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004961:Estramustine / Q000627:therapeutic use*; D005485:Flutamide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D009919:Orchiectomy; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000628:therapy*; D011897:Random Allocation
D000813:Anilides; D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D005485:Flutamide
Komplete Androgenblockade (Orchiektomie + Flutamid) versus Androgenblockade mit Zytostase (Orchiektomie + Estramustin) in der Behandlung des virginellen fortgeschrittenen Prostatakarzinoms.